• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

转移性复发性乳腺癌患者的实用预后指数:来自西班牙 GEICAM El Alamo 注册中心的 2322 例患者的回顾性分析。

Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register.

机构信息

Medical Oncology Department, Hospital Clínico San Carlos, C/Martín Lagos s/n, 28040, Madrid, Spain.

出版信息

Breast Cancer Res Treat. 2010 Jul;122(2):591-600. doi: 10.1007/s10549-009-0687-4. Epub 2010 Jan 10.

DOI:10.1007/s10549-009-0687-4
PMID:20063196
Abstract

Women with recurrent metastatic breast cancer from a Spanish hospital registry (El Alamo, GEICAM) were analyzed in order to identify the most helpful prognostic factors to predict survival and to ultimately construct a practical prognostic index. The inclusion criteria covered women patients diagnosed with operable invasive breast cancer who had metastatic recurrence between 1990 and 1997 in GEICAM hospitals. Patients with stage IV breast cancer at initial diagnosis or with isolated loco-regional recurrence were excluded from this analysis. Data from 2,322 patients with recurrent breast cancer after primary treatment (surgery, radiation and systemic adjuvant treatment) were used to construct the prognostic index. The prognostic index score for each individual patient was calculated by totalling up the scores of each independent variable. The maximum score obtainable was 26.1. Nine-hundred and sixty-two patients who had complete data for all the variables were used in the computation of the prognostic index score. We were able to stratify them into three prognostic groups based on the prognostic index score: 322 patients in the good risk group (score < or =13.5), 308 patients in the intermediate risk group (score 13.51-15.60) and 332 patients in the poor risk group (score > or =15.61). The median survivals for these groups were 3.69, 2.27 and 1.02 years, respectively (P < 0.0001). In conclusion, risk scores are extraordinarily valuable tools, highly recommendable in the clinical practice.

摘要

来自西班牙一家医院注册中心(El Alamo,GEICAM)的复发性转移性乳腺癌女性患者被分析,目的是确定最有助于预测生存的预后因素,并最终构建一个实用的预后指数。纳入标准涵盖了在 GEICAM 医院被诊断为可手术性浸润性乳腺癌且在 1990 年至 1997 年间发生转移性复发的女性患者。本分析排除了初诊时即患有 IV 期乳腺癌或仅发生局部区域性复发的患者。使用 2322 例在原发性治疗(手术、放疗和全身辅助治疗)后发生复发性乳腺癌患者的数据构建了预后指数。通过累加每个独立变量的得分来计算每个患者的预后指数得分。患者的最高得分为 26.1 分。962 例患者的所有变量数据完整,用于计算预后指数得分。我们能够根据预后指数得分将他们分为三个预后组:322 例患者为低危组(得分<或=13.5),308 例患者为中危组(得分 13.51-15.60),332 例患者为高危组(得分>或=15.61)。这些组的中位生存时间分别为 3.69、2.27 和 1.02 年(P<0.0001)。总之,风险评分是非常有价值的工具,在临床实践中强烈推荐使用。

相似文献

1
Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register.转移性复发性乳腺癌患者的实用预后指数:来自西班牙 GEICAM El Alamo 注册中心的 2322 例患者的回顾性分析。
Breast Cancer Res Treat. 2010 Jul;122(2):591-600. doi: 10.1007/s10549-009-0687-4. Epub 2010 Jan 10.
2
Brain metastases in breast cancer: prognostic factors and management.乳腺癌脑转移:预后因素与治疗
Breast Cancer Res Treat. 2008 Oct;111(3):523-30. doi: 10.1007/s10549-007-9806-2. Epub 2007 Nov 8.
3
Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM).辅助化疗开始时间对乳腺癌生存的影响:西班牙乳腺癌研究小组(GEICAM)的一项阴性结果研究
Breast Cancer Res Treat. 2007 Jan;101(2):215-23. doi: 10.1007/s10549-006-9282-0. Epub 2006 Jul 6.
4
External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.在一家欧洲中心,通过常规病理学方法对 Mayo 临床分期、大小、分级和坏死(SSIGN)评分在透明细胞肾细胞癌中的应用进行外部验证。
Eur Urol. 2010 Jan;57(1):102-9. doi: 10.1016/j.eururo.2008.11.033. Epub 2008 Nov 28.
5
259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.应用USC/范纽斯预后指数的259例乳腺导管原位癌患者:长期随访的回顾性研究
Breast Cancer Res Treat. 2008 Jun;109(3):405-16. doi: 10.1007/s10549-007-9668-7. Epub 2007 Aug 9.
6
Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer.预后因素及风险分组在分化型甲状腺癌管理中的意义
Laryngoscope. 2004 Mar;114(3):393-402. doi: 10.1097/00005537-200403000-00001.
7
[Breast-conservation treatment for early invasive breast cancer: prognostic factors for survival after salvage treatment of local recurrence].[早期浸润性乳腺癌的保乳治疗:局部复发挽救治疗后生存的预后因素]
Magy Onkol. 2007;51(2):127-31. Epub 2007 Jul 29.
8
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.基于新辅助内分泌治疗后肿瘤特征的雌激素受体阳性乳腺癌预后预测
J Natl Cancer Inst. 2008 Oct 1;100(19):1380-8. doi: 10.1093/jnci/djn309. Epub 2008 Sep 23.
9
The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.终末期肝病评分模型是人类免疫缺陷病毒1感染的终末期肝病患者最佳的预后因素:一项前瞻性队列研究。
Liver Transpl. 2009 Sep;15(9):1133-41. doi: 10.1002/lt.21735.
10
Prognostic index score and clinical prediction model of local regional recurrence after mastectomy in breast cancer patients.乳腺癌患者乳房切除术后局部区域复发的预后指数评分及临床预测模型
Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1401-9. doi: 10.1016/j.ijrobp.2005.11.015. Epub 2006 Feb 10.

引用本文的文献

1
Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer.帕博西尼治疗激素受体阳性、人表皮生长因子受体 2 阴性转移性乳腺癌的疗效、安全性和预测模型。
BMC Cancer. 2024 Jan 2;24(1):1. doi: 10.1186/s12885-023-11764-8.
2
A Novel Prognostic Nomogram for Predicting Survival of Hormone Receptor-Positive and HER2 Negative Advanced Breast Cancer Among the Han-Population.一种用于预测汉族人群激素受体阳性且人表皮生长因子受体2阴性晚期乳腺癌患者生存情况的新型预后列线图。
Front Oncol. 2022 Jul 1;12:918759. doi: 10.3389/fonc.2022.918759. eCollection 2022.
3
Using population-based data to evaluate the impact of adherence to endocrine therapy on survival in breast cancer through the web-application BreCanSurvPred.
利用基于人群的数据,通过网络应用程序 BreCanSurvPred 评估内分泌治疗依从性对乳腺癌生存的影响。
Sci Rep. 2022 May 16;12(1):8097. doi: 10.1038/s41598-022-12228-y.
4
Prognostic factors for patients with metastatic breast cancer: a literature review.转移性乳腺癌患者的预后因素:文献综述
Transl Cancer Res. 2021 Apr;10(4):1644-1655. doi: 10.21037/tcr-20-2119.
5
Prognostic Score for Metastatic Breast Cancer With Liver Metastasis and Its Predictive Value of Locoregional Treatment Benefit.伴有肝转移的转移性乳腺癌的预后评分及其对局部区域治疗获益的预测价值
Front Oncol. 2021 Aug 27;11:651636. doi: 10.3389/fonc.2021.651636. eCollection 2021.
6
Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus.建立预测 HR 阳性、HER2 阴性转移性乳腺癌患者接受依维莫司治疗的生存预后列线图。
Drug Des Devel Ther. 2021 Aug 10;15:3463-3473. doi: 10.2147/DDDT.S314723. eCollection 2021.
7
Prognostic Model for De Novo and Recurrent Metastatic Breast Cancer.新发和复发性转移性乳腺癌的预后模型
JCO Clin Cancer Inform. 2021 Aug;5:789-804. doi: 10.1200/CCI.21.00020.
8
Risk Factors and Survival of Patients With Liver Metastases at Initial Metastatic Breast Cancer Diagnosis in Han Population.汉族人群初诊转移性乳腺癌时肝转移患者的危险因素及生存情况
Front Oncol. 2021 May 11;11:670723. doi: 10.3389/fonc.2021.670723. eCollection 2021.
9
Prognostic factors in metastatic breast cancer: a prospective single-centre cohort study in a Finnish University Hospital.转移性乳腺癌的预后因素:芬兰大学医院的前瞻性单中心队列研究。
BMJ Open. 2020 Oct 12;10(10):e038798. doi: 10.1136/bmjopen-2020-038798.
10
A Prognostic Model for Breast Cancer With Liver Metastasis.一种用于伴有肝转移的乳腺癌的预后模型。
Front Oncol. 2020 Sep 2;10:1342. doi: 10.3389/fonc.2020.01342. eCollection 2020.